The DOI matches its Crossref record; 171 of the 171 references it cites were found in a registry or an index.
Evolving therapies for liver fibrosis
Open accessAbstract
Fibrosis is an intrinsic response to chronic injury, maintaining organ integrity when extensive necrosis or apoptosis occurs. With protracted damage, fibrosis can progress toward excessive scarring and organ failure, as in liver cirrhosis. To date, antifibrotic treatment of fibrosis represents an unconquered area for drug development, with enormous potential but also high risks. Preclinical research has yielded numerous targets for antifibrotic agents, some of which have entered early-phase clinical studies, but progress has been hampered due to the relative lack of sensitive and specific biomarkers to measure fibrosis progression or reversal. Here we focus on antifibrotic approaches for liver that address specific cell types and functional units that orchestrate fibrotic wound healing responses and have a sound preclinical database or antifibrotic activity in early clinical trials. We also touch upon relevant clinical study endpoints, optimal study design, and developments in fibrosis imaging and biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269 · cited 1×
“, facilitating cancer growth as tumorassociated macrophages) (18, 94, 95).”
Alternative activation of macrophages: mechanism and functions
Gordon, S., & Martinez, F. O. (2010) · Immunity · doi:10.1016/j.immuni.2010.05.007 · Cited by 4,197
Mechanisms of fibrosis: therapeutic translation for fibrotic disease
Wynn, T. A., & Ramalingam, T. R. (2012) · Nature Medicine · doi:10.1038/nm.2807 · Cited by 3,541 · cited 3×
“TGF-β and, to a lesser degree, its downstream mediator, connective tissue growth factor (CTGF), are potent profibrogenic cytokines for hepatic stellate cells/myofibroblasts (1, 2, 6, 9, 10, 18, 19).”
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Mechanisms of Hepatic Fibrogenesis
Friedman, S. L. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.003 · Cited by 2,634
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials
Noble, P. W., Albera, C., Bradford, W. Z., Costabel, U., Glassberg, M. K., Kardatzke, D., King, T. E., Lancaster, L., Sahn, S. A., Szwarcberg, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60405-4 · Cited by 2,154
Schuppan, D., & Afdhal, N. H. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60383-9 · Cited by 2,089
Self-citationAlcoholic Liver Disease: Pathogenesis and New Therapeutic Targets
Gao, B., & Bataller, R. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.09.002 · Cited by 1,963
TLR4 enhances TGF-β signaling and hepatic fibrosis
Seki, E., De Minicis, S., Österreicher, C. H., Kluwe, J., Osawa, Y., Brenner, D. A., & Schwabe, R. F. (2007) · Nature Medicine · doi:10.1038/nm1663 · Cited by 1,942
A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis
Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827
Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788
Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways
Tedgui, A., & Mallat, Z. (2006) · Physiological Reviews · doi:10.1152/physrev.00024.2005 · Cited by 1,701
Targeting IL-17 and TH17 cells in chronic inflammation
Miossec, P., & Kolls, J. K. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3794 · Cited by 1,414
Macrophages: master regulators of inflammation and fibrosis
Wynn, T., & Barron, L. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255354 · Cited by 1,392
Recent Developments in Myofibroblast Biology
Hinz, B., Phan, S. H., Thannickal, V. J., Prunotto, M., Desmoulière, A., Varga, J., De Wever, O., Mareel, M., & Gabbiani, G. (2012) · The American Journal of Pathology · doi:10.1016/j.ajpath.2012.02.004 · Cited by 1,193
Ripoll, C., Groszmann, R., Garcia–Tsao, G., Grace, N., Burroughs, A., Planas, R., Escorsell, A., Garcia–Pagan, J. C., Makuch, R., Patch, D., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.024 · Cited by 1,183
Efficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Poynard, T., McHutchison, J., Manns, M., Trepo, C., Lindsay, K., Goodman, Z., Ling, M., & Albrecht, J. (2002) · Gastroenterology · doi:10.1053/gast.2002.33023 · Cited by 1,146
Ramachandran, P., Pellicoro, A., Vernon, M. A., Boulter, L., Aucott, R. L., Ali, A., Hartland, S. N., Snowdon, V. K., Cappon, A., Gordon-Walker, T. T., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1119964109 · Cited by 1,001 · cited 1×
“A recent study demonstrated that fibrolytic macrophages in liver fibrosis derive from circulating Ly6Chi-expressing monocytes and develop locally into Ly6Clo-expressing macrophages with some classical M2 markers and a high expression of fibrolytic MMPs, and this development depends on phagocytic activity (96).”
Lipid-like materials for low-dose, in vivo gene silencing
Love, K. T., Mahon, K. P., Levins, C. G., Whitehead, K. A., Querbes, W., Dorkin, J. R., Qin, J., Cantley, W., Qin, L. L., Racie, T., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910603106 · Cited by 969
High-Dose Acetylcysteine in Idiopathic Pulmonary Fibrosis
Demedts, M., Behr, J., Buhl, R., Costabel, U., Dekhuijzen, R., Jansen, H. M., MacNee, W., Thomeer, M., Wallaert, B., Laurent, F., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042976 · Cited by 964
Pirfenidone in idiopathic pulmonary fibrosis
Taniguchi, H., Ebina, M., Kondoh, Y., Ogura, T., Azuma, A., Suga, M., Taguchi, Y., Takahashi, H., Nakata, K., Sato, A., et al. (2010) · European Respiratory Journal · doi:10.1183/09031936.00005209 · Cited by 946
Lee, C. G., Homer, R. J., Zhu, Z., Lanone, S., Wang, X., Koteliansky, V., Shipley, J. M., Gotwals, P., Noble, P., Chen, Q., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.809 · Cited by 940
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Pulmonary fibrosis: pathogenesis, etiology and regulation
Wilson, M. S., & Wynn, T. A. (2009) · Mucosal Immunology · doi:10.1038/mi.2008.85 · Cited by 822
Myofibroblasts revert to an inactive phenotype during regression of liver fibrosis
Kisseleva, T., Cong, M., Paik, Y., Scholten, D., Jiang, C., Benner, C., Iwaisako, K., Moore-Morris, T., Scott, B., Tsukamoto, H., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1201840109 · Cited by 805
Pirfenidone in idiopathic pulmonary fibrosis: Figure 1–
Swigris, J., & Fairclough, D. (2010) · European Respiratory Journal · doi:10.1183/09031936.00071710 · Cited by 799
Karlmark, K. R., Weiskirchen, R., Zimmermann, H. W., Gassler, N., Ginhoux, F., Weber, C., Merad, M., Luedde, T., Trautwein, C., & Tacke, F. (2009) · Hepatology · doi:10.1002/hep.22950 · Cited by 782
A Multicenter, Controlled Trial of Ursodiol for the Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Balkau, B., Eschwège, E., Poupon, R., & the UDCA–PBC Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199105303242204 · Cited by 755
Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis
Harrison, S. A., Torgerson, S., Hayashi, P. H., Ward, J. A., & Schenker, S. (2003) · The American Journal of Gastroenterology · doi:10.1016/j.amjgastroenterol.2003.08.005 · Cited by 731
Magnetic Resonance Elastography for the Noninvasive Staging of Liver Fibrosis
Huwart, L., Sempoux, C., Vicaut, E., Salameh, N., Annet, L., Danse, E., Peeters, F., ter Beek, L. C., Rahier, J., Sinkus, R., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.076 · Cited by 731
Bleomycin and IL-1β–mediated pulmonary fibrosis is IL-17A dependent
Wilson, M. S., Madala, S. K., Ramalingam, T. R., Gochuico, B. R., Rosas, I. O., Cheever, A. W., & Wynn, T. A. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20092121 · Cited by 730
Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721
Meng, F., Wang, K., Aoyama, T., Grivennikov, S. I., Paik, Y., Scholten, D., Cong, M., Iwaisako, K., Liu, X., Zhang, M., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.05.049 · Cited by 711 · cited 2×
“Th17 cells secrete IL-17A, which drives fibrogenesis directly in myofibroblasts and indirectly via stimulation of TGF-β1 release from inflammatory cells (80, 82).”
Ferraioli, G., Tinelli, C., Dal Bello, B., Zicchetti, M., Filice, G., Filice, C., & on behalf of the Liver Fibrosis Study Group (2012) · Hepatology · doi:10.1002/hep.25936 · Cited by 667
Therapy for Fibrotic Diseases: Nearing the Starting Line
Friedman, S. L., Sheppard, D., Duffield, J. S., & Violette, S. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3004700 · Cited by 655
Frank-Kamenetsky, M., Grefhorst, A., Anderson, N. N., Racie, T. S., Bramlage, B., Akinc, A., Butler, D., Charisse, K., Dorkin, R., Fan, Y., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805434105 · Cited by 642
Sato, Y., Murase, K., Kato, J., Kobune, M., Sato, T., Kawano, Y., Takimoto, R., Takada, K., Miyanishi, K., Matsunaga, T., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1396 · Cited by 609
Noninvasive Methods to Assess Liver Disease in Patients With Hepatitis B or C
Castera, L. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.02.017 · Cited by 605
Evolving challenges in hepatic fibrosis
Friedman, S. L. (2010) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2010.97 · Cited by 581
Matrix as a Modulator of Hepatic Fibrogenesis
Schuppan, D., Ruehl, M., Somasundaram, R., & Hahn, E. G. (2001) · Seminars in Liver Disease · doi:10.1055/s-2001-17556 · Cited by 542
Self-citationMolecular Mechanisms of Lipotoxicity in Nonalcoholic Fatty Liver Disease
Malhi, H., & Gores, G. (2008) · Seminars in Liver Disease · doi:10.1055/s-0028-1091980 · Cited by 538
Deactivation of Hepatic Stellate Cells During Liver Fibrosis Resolution in Mice
Troeger, J. S., Mederacke, I., Gwak, G., Dapito, D. H., Mu, X., Hsu, C. C., Pradere, J., Friedman, R. A., & Schwabe, R. F. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.06.036 · Cited by 515
Lynch, L., Nowak, M., Varghese, B., Clark, J., Hogan, A. E., Toxavidis, V., Balk, S. P., O’Shea, D., O’Farrelly, C., & Exley, M. A. (2012) · Immunity · doi:10.1016/j.immuni.2012.06.016 · Cited by 512
Harnois, D. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505
Richardson, M. M., Jonsson, J. R., Powell, E. E., Brunt, E. M., Neuschwander–Tetri, B. A., Bhathal, P. S., Dixon, J. B., Weltman, M. D., Tilg, H., Moschen, A. R., et al. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.012 · Cited by 482 · cited 1×
“These biliary progenitors are more resistant to enhanced oxidative stress and hepatocyte death, such as induced by ASH, NASH, or severe post-trans-plant hepatitis C (55–60).”
BackgroundProlonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon
Di Bisceglie, A. M., Shiffman, M. L., Everson, G. T., Lindsay, K. L., Everhart, J. E., Wright, E. C., Lee, W. M., Lok, A. S., Bonkovsky, H. L., Morgan, T. R., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0707615 · Cited by 465
A Placebo-Controlled Randomized Trial of Warfarin in Idiopathic Pulmonary Fibrosis
Noth, I., Anstrom, K. J., Calvert, S. B., de Andrade, J., Flaherty, K. R., Glazer, C., Kaner, R. J., & Olman, M. A. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201202-0314oc · Cited by 463
Issa, R., Zhou, X., Constandinou, C. M., Fallowfield, J., Millward-Sadler, H., Gaca, M. D. A., Sands, E., Suliman, I., Trim, N., & Knorr, A. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.03.009 · Cited by 456
CCR1 and CCR5 promote hepatic fibrosis in mice
Seki, E., De Minicis, S., Gwak, G.-Y., Kluwe, J., Inokuchi, S., Bursill, C. A., Llovet, J. M., Brenner, D. A., & Schwabe, R. F. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37444 · Cited by 431
Noninvasive assessment of liver fibrosis
Martínez, S. M., Crespo, G., Navasa, M., & Forns, X. (2011) · Hepatology · doi:10.1002/hep.24013 · Cited by 422
Clinical evidence for the regression of liver fibrosis
Ellis, E. L., & Mann, D. A. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.024 · Cited by 411
KANG, D.-H., JOLY, A. H., OH, S.-W., HUGO, C., KERJASCHKI, D., GORDON, K. L., MAZZALI, M., JEFFERSON, J. A., HUGHES, J., MADSEN, K. M., et al. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271434 · Cited by 411
An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection
Wynn, T. A., Cheever, A. W., Jankovic, D., Poindexter, R. W., Caspar, P., Lewis, F. A., & Sher, A. (1995) · Nature · doi:10.1038/376594a0 · Cited by 403
Diagnosis and Quantitation of Fibrosis
Manning, D. S., & Afdhal, N. H. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.001 · Cited by 399
KANG, D.-H., HUGHES, J., MAZZALI, M., SCHREINER, G. F., & JOHNSON, R. J. (2001) · Journal of the American Society of Nephrology · doi:10.1681/asn.v1271448 · Cited by 390
Reversal of Hepatic Fibrosis — Fact or Fantasy?
Friedman, S. L., & Bansal, M. B. (2006) · Hepatology · doi:10.1002/hep.20974 · Cited by 379
Integrins as therapeutic targets
Goodman, S. L., & Picard, M. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.04.002 · Cited by 376
Imatinib Treatment for Idiopathic Pulmonary Fibrosis: Randomized Placebo-controlled Trial Results
Daniels, C. E., Lasky, J. A., Limper, A. H., Mieras, K., Gabor, E., & Schroeder, D. R. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200906-0964oc · Cited by 373
Treatment of Idiopathic Pulmonary Fibrosis with Etanercept: An Exploratory, Placebo-controlled Trial
Raghu, G., Brown, K. K., Costabel, U., Cottin, V., du Bois, R. M., Lasky, J. A., Thomeer, M., Utz, J. P., Khandker, R. K., McDermott, L., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200709-1446oc · Cited by 370
Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., LeNaour, G., Hartmann-Heurtier, A., Bruckert, E., & Poynard, T. (2010) · Hepatology · doi:10.1002/hep.23270 · Cited by 366
Pentoxifylline improves nonalcoholic steatohepatitis: A randomized placebo-controlled trial
Zein, C. O., Yerian, L. M., Gogate, P., Lopez, R., Kirwan, J. P., Feldstein, A. E., & McCullough, A. J. (2011) · Hepatology · doi:10.1002/hep.24544 · Cited by 356
Enhanced liver fibrosis test can predict clinical outcomes in patients with chronic liver disease
Parkes, J., Roderick, P., Harris, S., Day, C., Mutimer, D., Collier, J., Lombard, M., Alexander, G., Ramage, J., Dusheiko, G., et al. (2010) · Gut · doi:10.1136/gut.2009.203166 · Cited by 351
Omenetti, A., Porrello, A., Jung, Y., Yang, L., Popov, Y., Choi, S. S., Witek, R. P., Alpini, G., Venter, J., Vandongen, H. M., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35875 · Cited by 341
Self-citationA randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis
Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338
Corpechot, C., Carrat, F., Bonnand, A.-M., Poupon, R. E., & Poupon, R. (2000) · Hepatology · doi:10.1053/jhep.2000.20240 · Cited by 316
Zimmermann, H. W., Seidler, S., Nattermann, J., Gassler, N., Hellerbrand, C., Zernecke, A., Tischendorf, J. J. W., Luedde, T., Weiskirchen, R., Trautwein, C., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011049 · Cited by 310
Barron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304
Bariatric surgery for non-alcoholic steatohepatitis in obese patients
Chavez-Tapia, N. C., Tellez-Avila, F. I., Barrientos-Gutierrez, T., Mendez-Sanchez, N., Lizardi-Cervera, J., & Uribe, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007340.pub2 · Cited by 297
A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C†
Huang, H., Shiffman, M. L., Friedman, S., Venkatesh, R., Bzowej, N., Abar, O. T., Rowland, C. M., Catanese, J. J., Leong, D. U., Sninsky, J. J., et al. (2007) · Hepatology · doi:10.1002/hep.21695 · Cited by 297
Targeting Liver Fibrosis: Strategies for Development and Validation of Antifibrotic Therapies†
Popov, Y., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23123 · Cited by 296
Self-citationQuinolone-3-Diarylethers: A New Class of Antimalarial Drug
Nilsen, A., LaCrue, A. N., White, K. L., Forquer, I. P., Cross, R. M., Marfurt, J., Mather, M. W., Delves, M. J., Shackleford, D. M., Saenz, F. E., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005029 · Cited by 292
Reversibility of Hepatic Fibrosis in Autoimmune Hepatitis
Dufour, J.-F., DeLellis, R., & Kaplan, M. M. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-127-11-199712010-00006 · Cited by 290
The Progression of Liver Fibrosis Is Related with Overexpression of the miR-199 and 200 Families
Murakami, Y., Toyoda, H., Tanaka, M., Kuroda, M., Harada, Y., Matsuda, F., Tajima, A., Kosaka, N., Ochiya, T., & Shimotohno, K. (2011) · PLoS ONE · doi:10.1371/journal.pone.0016081 · Cited by 282
Wang, X. W., Heegaard, N. H. H., & Ørum, H. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.04.007 · Cited by 280
Portal fibroblasts: Underappreciated mediators of biliary fibrosis†
Dranoff, J. A., & Wells, R. G. (2010) · Hepatology · doi:10.1002/hep.23405 · Cited by 273
Thabut, D., & Shah, V. (2010) · Journal of Hepatology · doi:10.1016/j.jhep.2010.07.004 · Cited by 266
NKT-Associated Hedgehog and Osteopontin Drive Fibrogenesis in Non-Alcoholic Fatty Liver Disease
Syn, W.-K., Agboola, K. M., Swiderska, M., Michelotti, G. A., Liaskou, E., Pang, H., Xie, G., Philips, G., Chan, I. S., Karaca, G. F., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-301857 · Cited by 266
Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice
Berres, M.-L., Koenen, R. R., Rueland, A., Zaldivar, M. M., Heinrichs, D., Sahin, H., Schmitz, P., Streetz, K. L., Berg, T., Gassler, N., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci41732 · Cited by 263
Tugues, S., Fernandez-Varo, G., Muñoz-Luque, J., Ros, J., Arroyo, V., Rodés, J., Friedman, S. L., Carmeliet, P., Jiménez, W., & Morales-Ruiz, M. (2007) · Hepatology · doi:10.1002/hep.21921 · Cited by 261
Syn, W., Jung, Y., Omenetti, A., Abdelmalek, M., Guy, C. D., Yang, L., Wang, J., Witek, R. P., Fearing, C. M., Pereira, T. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.06.051 · Cited by 258
Karlmark, K. R., Zimmermann, H. W., Roderburg, C., Gassler, N., Wasmuth, H. E., Luedde, T., Trautwein, C., & Tacke, F. (2010) · Hepatology · doi:10.1002/hep.23894 · Cited by 249
Performance of serum marker panels for liver fibrosis in chronic hepatitis C
Parkes, J., Guha, I. N., Roderick, P., & Rosenberg, W. (2006) · Journal of Hepatology · doi:10.1016/j.jhep.2005.10.019 · Cited by 239
Obesity, diabetes mellitus, and liver fibrosis
Chiang, D. J., Pritchard, M. T., & Nagy, L. E. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00426.2010 · Cited by 236
The Role of Matrix Stiffness in Hepatic Stellate Cell Activation and Liver Fibrosis
Wells, R. G. (2005) · Journal of Clinical Gastroenterology · doi:10.1097/01.mcg.0000155516.02468.0f · Cited by 232
Innate immunity in alcoholic liver disease
Gao, B., Seki, E., Brenner, D. A., Friedman, S., Cohen, J. I., Nagy, L., Szabo, G., & Zakhari, S. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00537.2010 · Cited by 230
The Caspase Inhibitor IDN-6556 Attenuates Hepatic Injury and Fibrosis in the Bile Duct Ligated Mouse
Canbay, A., Feldstein, A., Baskin-Bey, E., Bronk, S. F., & Gores, G. J. (2004) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.060129 · Cited by 215
Mass-encoded synthetic biomarkers for multiplexed urinary monitoring of disease
Kwong, G. A., von Maltzahn, G., Murugappan, G., Abudayyeh, O., Mo, S., Papayannopoulos, I. A., Sverdlov, D. Y., Liu, S. B., Warren, A. D., Popov, Y., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2464 · Cited by 213
Self-citationNelson, D. R., Tu, Z., Soldevila-Pico, C., Abdelmalek, M., Zhu, H., Xu, Y. L., Cabrera, R., Liu, C., & Davis, G. L. (2003) · Hepatology · doi:10.1002/hep.1840380412 · Cited by 202
Patsenker, E., Popov, Y., Stickel, F., Jonczyk, A., Goodman, S. L., & Schuppan, D. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.04.009 · Cited by 200
Self-citationPrediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay
Mayo, M. J., Parkes, J., Adams-Huet, B., Combes, B., Mills, A. S., Markin, R. S., Rubin, R., Wheeler, D., Contos, M., West, A. B., et al. (2008) · Hepatology · doi:10.1002/hep.22517 · Cited by 198
Cathepsin B inactivation attenuates hepatic injury and fibrosis during cholestasis
Canbay, A., Guicciardi, M. E., Higuchi, H., Feldstein, A., Bronk, S. F., Rydzewski, R., Taniai, M., & Gores, G. J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17740 · Cited by 193
Park, O., Jeong, W.-I., Wang, L., Wang, H., Lian, Z.-X., Gershwin, E. M., & Gao, B. (2009) · Hepatology · doi:10.1002/hep.22813 · Cited by 189
Popov, Y., Patsenker, E., Stickel, F., Zaks, J., Bhaskar, K. R., Niedobitek, G., Kolb, A., Friess, H., & Schuppan, D. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.11.021 · Cited by 185
Self-citationTorres, D. M., Jones, F. J., Shaw, J. C., Williams, C. D., Ward, J. A., & Harrison, S. A. (2011) · Hepatology · doi:10.1002/hep.24558 · Cited by 183
The Role of Chemokines in Acute Liver Injury
Saiman, Y., & Friedman, S. L. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00213 · Cited by 180
Toll-Like Receptors in Liver Fibrosis: Cellular Crosstalk and Mechanisms
Yang, L., & Seki, E. (2012) · Frontiers in Physiology · doi:10.3389/fphys.2012.00138 · Cited by 176
Makowski, M. R., Wiethoff, A. J., Blume, U., Cuello, F., Warley, A., Jansen, C. H. P., Nagel, E., Razavi, R., Onthank, D. C., Cesati, R. R., et al. (2011) · Nature Medicine · doi:10.1038/nm.2310 · Cited by 175
Patsenker, E., Popov, Y., Stickel, F., Schneider, V., Ledermann, M., Sägesser, H., Niedobitek, G., Goodman, S. L., & Schuppan, D. (2009) · Hepatology · doi:10.1002/hep.23144 · Cited by 174
Self-citationCXC chemokine ligand 4 (Cxcl4) is a platelet‐derived mediator of experimental liver fibrosis†
Zaldivar, M. M., Pauels, K., von Hundelshausen, P., Berres, M., Schmitz, P., Bornemann, J., Kowalska, M. A., Gassler, N., Streetz, K. L., Weiskirchen, R., et al. (2010) · Hepatology · doi:10.1002/hep.23435 · Cited by 171
Suppression of hepatic stellate cell activation by microRNA-29b
Sekiya, Y., Ogawa, T., Yoshizato, K., Ikeda, K., & Kawada, N. (2011) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2011.07.041 · Cited by 168
Antifibrotic Effects of CXCL9 and Its Receptor CXCR3 in Livers of Mice and Humans
Wasmuth, H. E., Lammert, F., Zaldivar, M. M., Weiskirchen, R., Hellerbrand, C., Scholten, D., Berres, M.-L., Zimmermann, H., Streetz, K. L., Tacke, F., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.03.053 · Cited by 168
Kweon, Y.-O., Goodman, Z. D., Dienstag, J. L., Schiff, E. R., Brown, N. A., Burkhardt, E., Schoonhoven, R., Brenner, D. A., & Fried, M. W. (2001) · Journal of Hepatology · doi:10.1016/s0168-8278(01)00218-5 · Cited by 167
Jung, Y., Brown, K. D., Witek, R. P., Omenetti, A., Yang, L., Vandongen, M., Milton, R. J., Hines, I. N., Rippe, R. A., Spahr, L., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.022 · Cited by 167
Philips, G. M., Chan, I. S., Swiderska, M., Schroder, V. T., Guy, C., Karaca, G. F., Moylan, C., Venkatraman, T., Feuerlein, S., Syn, W.-K., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023943 · Cited by 165
Role of αvβ6 integrin in acute biliary fibrosis
Wang, B., Dolinski, B. M., Kikuchi, N., Leone, D. R., Peters, M. G., Weinreb, P. H., Violette, S. M., & Bissell, M. D. (2007) · Hepatology · doi:10.1002/hep.21849 · Cited by 163
Signals from dying hepatocytes trigger growth of liver progenitors
Jung, Y., Witek, R. P., Syn, W.-K., Choi, S. S., Omenetti, A., Premont, R., Guy, C. D., & Diehl, A. M. (2010) · Gut · doi:10.1136/gut.2009.204354 · Cited by 161
Adenosine signaling contributes to ethanol-induced fatty liver in mice
Peng, Z., Borea, P. A., Wilder, T., Yee, H., Chiriboga, L., Blackburn, M. R., Azzena, G., Resta, G., & Cronstein, B. N. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37409 · Cited by 160
Chemokines in Liver Inflammation and Fibrosis
Wasmuth, H., Tacke, F., & Trautwein, C. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255351 · Cited by 159
Natural killer and natural killer T cells in liver fibrosis
Gao, B., & Radaeva, S. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.09.008 · Cited by 158
Jiang, J. X., Mikami, K., Venugopal, S., Li, Y., & Török, N. J. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.024 · Cited by 158
Progression of liver fibrosis in post-transplant hepatitis C: Mechanisms, assessment and treatment
Berenguer, M., & Schuppan, D. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.014 · Cited by 155
Self-citationRole of TLR9 in hepatic stellate cells and experimental liver fibrosis
Gäbele, E., Mühlbauer, M., Dorn, C., Weiß, T. S., Froh, M., Schnabl, B., Wiest, R., Schölmerich, J., Obermeier, F., & Hellerbrand, C. (2008) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2008.08.096 · Cited by 150
Progression of fibrosis in hepatitis C with and without schistosomiasis
Kamal, S. M., Turner, B. S., He, Q., Rasenack, J. W. F., Bianchi, L., Tawil, A. A., Nooman, A., Massoud, M., Koziel, M. J., & Afdhal, N. H. (2006) · Hepatology · doi:10.1002/hep.21117 · Cited by 142
Jeong, W.-I., Park, O., Suh, Y.-G., Byun, J.-S., Park, S.-Y., Choi, E., Kim, J.-K., Ko, H., Wang, H., Miller, A. M., et al. (2011) · Hepatology · doi:10.1002/hep.24190 · Cited by 142
Mechanical Tension and Integrin α2β1 Regulate Fibroblast Functions
Eckes, B., Zweers, M. C., Zhang, Z., Hallinger, R., Mauch, C., Aumailley, M., & Krieg, T. M. (2006) · Journal of Investigative Dermatology Symposium Proceedings · doi:10.1038/sj.jidsymp.5650003 · Cited by 139
Popov, Y. V., Sverdlov, D., Sharma, A. K., Bhaskar, K. R., Li, S., Freitag, T. L., Lee, J. D., Dieterich, W., Melino, G., & Schuppan, D. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.01.040 · Cited by 137
Self-citationPuche, J. E., Lee, Y. A., Jiao, J., Aloman, C., Fiel, M. I., Muñoz, U., Kraus, T., Lee, T., Yee, H. F., & Friedman, S. L. (2013) · Hepatology · doi:10.1002/hep.26053 · Cited by 136
Popov, Y., Sverdlov, D. Y., Bhaskar, K. R., Sharma, A. K., Millonig, G., Patsenker, E., Krahenbuhl, S., Krahenbuhl, L., & Schuppan, D. (2010) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00394.2009 · Cited by 136
Self-citationChemokine Cxcl9 attenuates liver fibrosis-associated angiogenesis in mice
Sahin, H., Borkham‐Kamphorst, E., Kuppe, C., Zaldivar, M. M., Grouls, C., Alsamman, M., Nellen, A., Schmitz, P., Heinrichs, D., Berres, M., et al. (2012) · Hepatology · doi:10.1002/hep.25545 · Cited by 135
Precision-cut liver slices: A tool to model the liver ex vivo
Olinga, P., & Schuppan, D. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.009 · Cited by 124
Self-citationJiang, J. X., Venugopal, S. K., Serizawa, N., Chen, X., Scott, F., Li, Y., Adamson, R. H., Devaraj, S., Shah, V. H., Gershwin, M. E., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.05.074 · Cited by 123
Therapeutic targets in liver fibrosis
Fallowfield, J. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00451.2010 · Cited by 123
Colmenero, J., Bataller, R. A., Sancho‐Bru, P., Domínguez, M., Moreno, M., Forns, X., Bruguera, M., Arroyo, V., Brenner, D. A., & Ginès, P. (2009) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00162.2009 · Cited by 121
Stem cell therapies for liver failure and cirrhosis
Zhang, Z., & Wang, F. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.01.018 · Cited by 119
Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B
Liu, P. (2002) · World Journal of Gastroenterology · doi:10.3748/wjg.v8.i4.679 · Cited by 118
Poynard, T., Zoulim, F., Ratziu, V., Degos, F., Imbert‐Bismut, F., Dény, P., Landais, P., Hasnaoui, A. E., Slama, A., Blin, P., et al. (2005) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2005.41957.x · Cited by 118
Fang, F., Liu, L., Yang, Y., Tamaki, Z., Wei, J., Marangoni, R. G., Bhattacharyya, S., Summer, R. S., Ye, B., & Varga, J. (2012) · Arthritis Research & Therapy · doi:10.1186/ar4070 · Cited by 114
Pockros, P. J., Jeffers, L. J., Afdhal, N. H., Goodman, Z. D., Nelson, D. R., Gish, R. G., Reddy, K. R., Reindollar, R., Rodriguez‐Torres, M., Sullivan, S., et al. (2007) · Hepatology · doi:10.1002/hep.21561 · Cited by 111
Thabut, D., Routray, C., Lomberk, G. A., Shergill, U., Glaser, K. J., Huebert, R. C., Patel, L. S., Masyuk, T. V., Blechacz, B. R. A., Vercnocke, A. J., et al. (2011) · Hepatology · doi:10.1002/hep.24427 · Cited by 107
Role of integrins in fibrosing liver diseases
Patsenker, E., & Stickel, F. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00050.2011 · Cited by 104
Fibroproliferative Disorders and Their Mechanobiology
Huang, C., & Ogawa, R. (2012) · Connective Tissue Research · doi:10.3109/03008207.2011.642035 · Cited by 104
Clinical use of CCR5 inhibitors in HIV and beyond
Gilliam, B. L., Riedel, D. J., & Redfield, R. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-s1-s9 · Cited by 103
Kim, M. Y., Suk, K. T., Baik, S. K., Kim, H. A., Kim, Y. J., Cha, S. H., Kwak, H.-R., Cho, M.-Y., Park, H. J., Jeon, H. K., et al. (2012) · Hepatology · doi:10.1002/hep.25752 · Cited by 102
Self-citationNew horizons for stem cell therapy in liver disease
Forbes, S. J., & Newsome, P. N. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.06.022 · Cited by 102
Popov, Y. V., Patsenker, E., Bauer, M. W., Niedobitek, E., Schulze-Krebs, A., & Schuppan, D. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600030200 · Cited by 101
Self-citationFontana, R. J., Dienstag, J. L., Bonkovsky, H. L., Sterling, R. K., Naishadham, D., Goodman, Z. D., Lok, A. S.-F., Wright, E. C., Su, G. L., & the HALT-C Trial Group (2010) · Gut · doi:10.1136/gut.2010.207423 · Cited by 100
The phenotypic fate and functional role for bone marrow-derived stem cells in liver fibrosis
Kisseleva, T., & Brenner, D. A. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.09.021 · Cited by 99
Anti-fibrotic therapy: Lost in translation?
Schuppan, D., & Pinzani, M. (2012) · Journal of Hepatology · doi:10.1016/s0168-8278(12)60008-7 · Cited by 97
Self-citationNovel engineered targeted interferon-gamma blocks hepatic fibrogenesis in mice
Bansal, R., Prakash, J., Post, E., Beljaars, L., Schuppan, D., & Poelstra, K. (2011) · Hepatology · doi:10.1002/hep.24395 · Cited by 96
Self-citationKlein, S., van Beuge, M. M., Granzow, M., Beljaars, L., Schierwagen, R., Kilic, S., Heidari, I., Huss, S., Sauerbruch, T., Poelstra, K., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.07.033 · Cited by 93
Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection
McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91
Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term
Neef, M., Ledermann, M., Saegesser, H., Schneider, V., Widmer, N., Decosterd, L. A., Rochat, B., & Reichen, J. (2005) · Journal of Hepatology · doi:10.1016/j.jhep.2005.06.015 · Cited by 91
Mononuclear cells in liver fibrosis
Marra, F., Aleffi, S., Galastri, S., & Provenzano, A. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0169-0 · Cited by 90
PRM-151 (recombinant human serum amyloid P/pentraxin 2) for the treatment of fibrosis
Duffield, J. S., & Lupher, M. (2010) · Drug News & Perspectives · doi:10.1358/dnp.2010.23.5.1444206 · Cited by 84
Loss of myeloid cell-derived vascular endothelial growth factor accelerates fibrosis
Stockmann, C., Kerdiles, Y. M., Nomaksteinsky, M., Weidemann, A., Takeda, N., Doedens, A. L., Torres‐Collado, A. X., Iruela‐Arispe, M. L., Nizet, V., & Johnson, R. S. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912766107 · Cited by 83
Gonzalo, T., Beljaars, L., van de Bovenkamp, M., Temming, K., van Loenen-Weemaes, A. M., Reker‐Smit, C., Meijer, D. K. F., Lacombe, M., Opdam, F., Kéri, G., et al. (2007) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.114496 · Cited by 76
Kim, M. Y., Cho, M.-Y., Baik, S. K., Jeong, P. H., Suk, K. T., Jang, Y. O., Yea, C. J., Kim, J. W., Kim, H. S., Kwon, S. O., et al. (2012) · Liver International · doi:10.1111/j.1478-3231.2012.02774.x · Cited by 74
Mehal, W. Z., & Imaeda, A. B. (2010) · Seminars in Liver Disease · doi:10.1055/s-0030-1255352 · Cited by 73
Mechanisms of Disease Progression in NASH
Bohinc, B. N., & Diehl, A. M. (2012) · Clinics in Liver Disease · doi:10.1016/j.cld.2012.05.002 · Cited by 69
The Role of Matrix Stiffness in Hepatic Stellate Cell Activation and Liver Fibrosis
Gaça, M. D. A., Georges, P., Hui, J., Janmey, P., & Rg, W. (2005) · Wound Repair and Regeneration · doi:10.1111/j.1067-1927.2005.130117aa.x · Cited by 68
Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project
Couluris, M., Kinder, B. W., Xu, P., Gross-King, M., Krischer, J. P., & Panos, R. J. (2012) · Lung · doi:10.1007/s00408-012-9410-z · Cited by 67
Anti‐PDGF‐B monoclonal antibody reduces liver fibrosis development
Ogawa, S., Ochi, T., Shimada, H., Inagaki, K., Fujita, I., Nii, A., Moffat, M. A., Katragadda, M., Violand, B. N., Arch, R. H., et al. (2010) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00718.x · Cited by 63
Targeted therapy of liver fibrosis/cirrhosis and its complications
Poelstra, K., & Schuppan, D. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2011.04.008 · Cited by 62
Self-citationCXCR4 Inhibitors: Tumor Vasculature and Therapeutic Challenges
de Nigris, F., Schiano, C., Infante, T., & Claudio Napoli, A. (2012) · Recent Patents on Anti-Cancer Drug Discovery · doi:10.2174/157489212801820039 · Cited by 61
Targeted Drug Delivery Using Immunoconjugates: Principles and Applications
Pasquetto, M. V., Vecchia, L., Covini, D., Digilio, R., & Scotti, C. (2011) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318234ecf5 · Cited by 61
Mentink‐Kane, M. M., Cheever, A. W., Wilson, M. S., Madala, S. K., Beers, L. M., Ramalingam, T. R., & Wynn, T. A. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.08.008 · Cited by 60
Biomarkers of liver fibrosis: What lies beneath the receiver operating characteristic curve?
Guha, I. N., Myers, R. P., Patel, K., & Talwalkar, J. A. (2011) · Hepatology · doi:10.1002/hep.24515 · Cited by 58
Effect of Treatment of Hepatic Histopathology in Children and Adolescents With Autoimmune Hepatitis
Ferreira, A. R., Roquete, M. L. V., Toppa, N. H., de Castro, L. P. F., Fagundes, E. D. T., & Penna, F. J. (2008) · Journal of Pediatric Gastroenterology and Nutrition · doi:10.1097/01.mpg.0000304456.84552.13 · Cited by 50
13C-breath tests in the study of microsomal liver function.
Candelli, M., Cazzato, I. A., Zocco, M. A., Nista, E. C., Fini, L., Armuzzi, A., Camise, V., Santoro, M., Miele, L., Grieco, A., et al. (2004) · PubMed · Cited by 42
Barczyk, M. M., Lü, N., Popova, S. N., Bolstad, A. I., & Gullberg, D. (2012) · Journal of Cellular Physiology · doi:10.1002/jcp.24261 · Cited by 41
Regulation of Matrix Synthesis, Remodeling and Accumulation in Glomerulosclerosis
Pozzi, A., Voziyan, P., Hudson, B. G., & Zent, R. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209787846748 · Cited by 40
Toll-like receptor-4 antagonist eritoran tetrasodium for severe sepsis
Tidswell, M., & LaRosa, S. P. (2011) · Expert Review of Anti-infective Therapy · doi:10.1586/eri.11.27 · Cited by 38
Th17 Cells Regulate Liver Fibrosis by Targeting Multiple Cell Types: Many Birds With One Stone
Gao, B., & Waisman, A. (2012) · Gastroenterology · doi:10.1053/j.gastro.2012.07.031 · Cited by 33
Epithelial-to-Mesenchymal Transition in Liver Fibrosis: Dead or Alive?
Popov, Y. V., & Schuppan, D. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.07.015 · Cited by 32
Self-citationARTEMIS-IPF: A Placebo-Controlled Trial Of Ambrisentan In Idiopathic Pulmonary Fibrosis
Raghu, G., Behr, J., Brown, K. M., Egan, J. J., Kawut, S. M., Flaherty, K. R., Martínez, F. J., Nathan, S. D., Wells, A. U., Pedersen, P. S., et al. (2012) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a3632 · Cited by 19
Gómez, E. V., Oramas, B. G., Soler, E. A., Navarro, R. L., & Domech, C. R. (2007) · Liver International · doi:10.1111/j.1478-3231.2006.01411.x · Cited by 18
Gabrielli, G. B., Casaril, M., Stanzial, A. M., Colombari, R., Pasino, M., & Corrocher, R. (2003) · PubMed · Cited by 5
Cited by
Mederacke, I., Hsu, C. C., Troeger, J. S., Huebener, P., Mu, X., Dapito, D. H., Pradere, J.-P., & Schwabe, R. F. (2013) · Nature Communications · doi:10.1038/ncomms3823 · Cited by 1,443
Macrophage heterogeneity in liver injury and fibrosis
Tacke, F., & Zimmermann, H. W. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2013.12.025 · Cited by 1,061
The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
Kazankov, K., Jørgensen, S. M. D., Thomsen, K. L., Møller, H. J., Vilstrup, H., George, J., Schuppan, D., & Grønbæk, H. (2019) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-018-0082-x · Cited by 941
Self-citationPathobiology of liver fibrosis: a translational success story
Lee, Y. A., Wallace, M. C., & Friedman, S. L. (2015) · Gut · doi:10.1136/gutjnl-2014-306842 · Cited by 894
Cell Death and Cell Death Responses in Liver Disease: Mechanisms and Clinical Relevance
Luedde, T., Kaplowitz, N., & Schwabe, R. F. (2014) · Gastroenterology · doi:10.1053/j.gastro.2014.07.018 · Cited by 759
Metadata
- Authors
- Schuppan, D., & Kim, Y. O.
- Venue
- Journal of Clinical Investigation
- Published
- 2013-05-01
- Volume
- 123
- Issue
- 5
- Pages
- 1887-1901
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1981262534
- Cited by
- 595
- References
- 171
- FWCI
- 39.82
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.